Investigation of Conversion Surgery for Initial UR-PDAC: Is Adjuvant Chemotherapy Still Necessary?-Reference-Cited by-同舟云学术

Investigation of Conversion Surgery for Initial UR-PDAC: Is Adjuvant Chemotherapy Still Necessary?

Published:2021-10-01 Issue:10 Volume:54 Page:665-678
ISSN:0386-9768
Container-title:The Japanese Journal of Gastroenterological Surgery
language:en
Short-container-title:Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi

Author:

Yamada Daisaku¹^ORCID,Takahashi Hidenori¹,Mukai Yosuke¹,Asukai Kei¹,Hasegawa Shinichiro¹,Wada Hiroshi¹,Matsuda Chu¹,Yasui Masayoshi¹,Omori Takeshi¹,Miyata Hiroshi¹

Affiliation:

1. Department of Gastroenterological Surgery, Osaka International Cancer Institute

Publisher

The Japanese Journal of Gastroenterological Surgery

Subject

Gastroenterology,Surgery

Link

https://www.jstage.jst.go.jp/article/jjgs/54/10/54_2020.0166/_pdf

Reference34 articles.

1. 1) Takahashi H, Yamada D, Asukai K, Wada H, Hasegawa S, Hara H, et al. Clinical implications of the serum ca19-9 level in “biological borderline resectability” and “biological downstaging” in the setting of preoperative chemoradiation therapy for pancreatic cancer. Pancreatology. 2020;20(5):919–928.

2. 2) Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.

3. 3) Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.

4. 4) Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today. 2019;49(11):894–906.

5. 5) Hank T, Strobel O. Conversion surgery for advanced pancreatic cancer. J Clin Med. 2019;8(11):e1–e18.